Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosisarticle Published on 2023-05-122024-09-05 Journal: Thrombosis and haemostasis [Category] update2024, [키워드] Antiplatelet agent artificial surfaces Atherosclerosis Oral anticoagulants thrombosis [DOI] 10.1055/a-2052-9175 PMC 바로가기 [Article Type] article
Risk of thrombotic events and other complications in anticoagulant users infected with SARS-CoV-2: an observational cohort study in primary health care in SIDIAP (Catalonia, Spain)Observational Study Published on 2022-06-082022-10-05 Journal: BMC primary care [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI age age and gender analyzed Anticoagulant applied Care Cohort Comorbidity Complication COVID-19 COVID-19 complication database death Diagnosis Electronic health records events Frequency group had more Health higher risk Hospital admission Hospitalization Hospitalized increased risk individuals with COVID-19 Intervention lower risk mortality rate not different OAC Observational cohort study Older oral oral anticoagulant Oral anticoagulants outcome Patient Pneumonia Primary Health Care propensity score matching risk Spain stroke System Thromboembolic event Thromboembolic events thrombotic event Thrombotic events treated with COVID-19 women [DOI] 10.1186/s12875-022-01752-5 PMC 바로가기 [Article Type] Observational Study
Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study저산소증 성인 COVID-19에 대한 바리시티닙, 렘데시비르 및 덱사메타손 조합의 효능: 후향적 연구Article Published on 2022-05-012022-09-11 Journal: Respiratory medicine and research [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] abnormality adjusted Admission analyzed Bacterial infection Baricitinib C-reactive protein chest X-ray city Combination combination therapy confidential interval consecutive patients control group coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients Dexamethasone effective Efficacy Evidence faster Gray hypoxic hypoxic patient hypoxic patients incidence investigated median Oral anticoagulants oxygen Oxygen therapy Patient patients rate ratio receiving regression analysis Remdesivir required Retrospective study significantly higher tolerable with COVID-19 [DOI] 10.1016/j.resmer.2022.100903 PMC 바로가기 [Article Type] Article
Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 casesReview Published on 2021-12-202022-10-31 Journal: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery [Category] COVID-19, [키워드] accumulating ChAdOx1-S coronavirus COVID vaccines COVID-19 Diagnosis discharged Evidence female first dose hypercoagulability immune literature review majority male occur occurred Oral anticoagulants outcome Partial Pathogenesis Patient patients patients died ranged reported SARS-CoV-2 SARS-CoV-2 vaccination second dose steroid thrombosis thrombotic Treatment vaccination Vaccine venous VST [DOI] 10.1186/s41983-021-00431-z PMC 바로가기 [Article Type] Review
COVID-19 and renal infarct: To be or not to be on anticoagulationCase Report Published on 2021-11-092022-11-01 Journal: Clinical Nephrology. Case Studies [Category] COVID-19, [키워드] adverse outcomes anticoagulation antiplatelet approach arterial thrombi Aspirin Castleman disease clinician Complication COVID-19 COVID-19 diagnosis Diagnosis disease high risk highlight Infection inpatient admission low-dose male management medical resource Mild morbidity Oral anticoagulants Patient presenting Pulmonary emboli renal Renal Infarction risk spleen infarct therapy thrombosis thrombotic complication unique Vascular vascular thrombosis venous with COVID-19 [DOI] 10.5414/CNCS110602 PMC 바로가기 [Article Type] Case Report
Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation샤가스병과 코로나19의 면역혈전 조절장애: 항응고제 비교 연구Comparative Study Published on 2021-10-012022-09-12 Journal: Molecular and cellular biochemistry [Category] MERS, SARS, 진단, [키워드] anticoagulation caused Chagas disease Characteristics COVID-19 disease dysregulated dysregulation etiological agent Factors Hyperaggregability hypercoagulability immunothrombosis Inflammation mechanism Oral anticoagulants PAMPs pathogen-associated molecular pattern Platelet SARS-CoV-2 similarity Treatment Trypanosoma cruzi vascular leakage [DOI] 10.1007/s11010-021-04204-3 PMC 바로가기 [Article Type] Comparative Study
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trialRandomized Controlled Trial Published on 2021-06-122022-10-05 Journal: Lancet (London, England) [Category] SARS, 임상, [키워드] 1:1 absence allergic reaction analysed Analysis anticoagulation assigned Bayer bleeding blinded Brazil clinical outcomes clinically Coalition Concentration Controlled trial COVID-19 COVID-19 symptom D-dimer death duration of hospitalisation Efficacy Efficacy and safety elevated Follow-up Hierarchical hospital hospitalised IMPROVE improve clinical outcome In-hospital initial intention-to-treat population intravenous medication multicentre not different occurred one patient Open-label Oral anticoagulants outcome Patient patients per day Pragmatic primary analysis Prophylactic prophylactic anticoagulation prothrombotic state randomisation randomised Randomly receive reflect Registered risk screened Seven supplemental oxygen therapeutic therapeutic anticoagulation unfractionated heparin with COVID-19 withdrawal of consent [DOI] 10.1016/S0140-6736(21)01203-4 PMC 바로가기 [Article Type] Randomized Controlled Trial
Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 PatientsOriginal Article Published on 2021-05-142022-10-31 Journal: Cardiovascular Drugs and Therapy [Category] COVID-19, [키워드] acute respiratory distress Admission antagonist anticoagulation ARDS association assumption benefit chronic clinical Clinical course Clinical outcome comparable confounder consecutive patient Coronary artery disease COVID-19 death diabetes high risk Hospitalization Hospitalized hospitalized patient hospitals hypertension in-hospital mortality Italian Italian study Mortality multicenter no difference NOAC NOACs OAT Older oral oral anticoagulant Oral anticoagulants outcome Patient patients hospitalized patients treated previous study propensity score matching reported Result retrospective risk SARS-CoV-2 syndrome therapy Thromboembolic events Treatment two group VKA with COVID-19 [DOI] 10.1007/s10557-021-07194-y PMC 바로가기 [Article Type] Original Article
Inflammation and thrombosis in patients with COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2Review Published on 2020-10-242023-06-15 Journal: Anatolian journal of cardiology [Category] MERS, SARS, [키워드] antithrombotic therapy clinical outcomes COVID-19 D-dimer Disseminated intravascular coagulation heparin Inflammation Low molecular weight heparins Oral anticoagulants SARS-CoV-2 thrombosis [DOI] 10.14744/AnatolJCardiol.2020.56727 PMC 바로가기 [Article Type] Review
Managing anticoagulation in the COVID-19 era between lockdown and reopening phasesIM-Point of view Published on 2020-06-082022-10-30 Journal: Internal and Emergency Medicine [Category] Coronavirus, MERS, SARS, [키워드] activity Anticoagulant Anticoagulant treatment anticoagulation COVID-19 COVID-19 pandemic diffusion DOAC Federation Guidance highest Italian Italy lockdown managing non-infected offer Oral anticoagulants pandemic Patient Patient care patients Prevalence Prevent Surveillance total population virus Warfarin [DOI] 10.1007/s11739-020-02391-3 PMC 바로가기 [Article Type] IM-Point of view